Gain-of-function mutations in fibroblast growth factor receptor (FGFR) genes are known to cause a range of skeletal disorders, such as craniosynostosis and chondrodysplasia, which severely affect ...

A promising new targeted cancer therapy is now available to certain patients with advanced pancreatic cancer – from the comfort of their home. The treatment is available through a first-of-its-kind, ...

PHILADELPHIA— The first bladder cancer drug targeting a cancer-driving gene mutation has been used relatively little despite its clear efficacy in a clinical trial, suggests a study from researchers ...

Drugs targeting FGFR mutations, which are seen in patients with intrahepatic cholangiocarcinoma (CCA), have generated particular excitement; the authors note that prior to the approval of pemigatinib, ...

Investigators also confirmed that FGFR2 fusion–positive tumors have a higher expression of FGFR2 but were not associated with higher expression of FGFR1, FGFR3, or FGFR4. Investigators concluded that ...

The first bladder cancer drug targeting a cancer-driving gene mutation has been used relatively little despite its clear efficacy in a clinical trial, suggests a study from researchers at the Perelman ...

Molecular Correlates of Long-Term Response to Bevacizumab in Glioblastoma Recurrent nonkinase domain FGFR VUS variants were collected from the Catalog of Somatic Mutations in Cancer and their ...

H.E. is supported by the Irving W. Janock Fellowship. L.G. is supported by the American Cancer Society Clinical Scientist Development Grant 134013‐CSDG‐19‐163‐01‐TBG. The following represents ...

COLUMBUS, Ohio. (Ivanhoe Newswire) - About 64,000 Americans will be diagnosed with pancreatic cancer this year, and over 50,000 will die from it. Health experts say it’s a hard cancer to cure because ...

Please provide your email address to receive an email when new articles are posted on . Researchers are launching an all-telehealth precision oncology trial that will include patients with pancreatic ...